Either ACEi or ARB therapy protect against kidney failure in those with advanced CKD

July 16, 2024
Neither therapy provided a death benefit for those with late-stage CKD.

A systematic review and retrospective individual participant-level meta-analysis of 18 trials comprised of more than 1,700 participants found that initiating treatment with an angiotensin-converting enzyme inhibitor (ACEi) or angiotensin-receptor blocker (ARB) protects against kidney failure in patients with advanced chronic kidney disease (CKD).

Neither therapy provided a death benefit. The findings are published in Annals of Internal Medicine.

Researchers from the University of California, San Francisco and Tufts Medical Center conducted an individual level analysis of 18 trials to examine the association of ACEi or ARB treatment initiation, relative to a non–ACEi or ARB comparator, with rates of kidney failure and death. The data showed that the risk for progression to kidney failure and replacement therapy (KFRT) was reduced by 34% in those with advanced CKD who initiated treatment with an ACEI or ARB, however, neither ACEi nor ARB treatment initiation affected risk for death. The effect of ACEis or ARBs did not vary by age, estimated glomerular filtration rate (eGFR), albuminuria, or history of diabetes for the outcome of kidney failure or death; however, there may have been a signal that the effect was less pronounced in those with diabetes for the outcome of KFRT. According to the study authors, these findings suggest that initiation of treatment with an ACEi or ARB may be beneficial to patients with late-stage CKD.

ACP release on Newswise

By WindyNight on Adobe Stock
adobestock_296464233
ID 373539758 © Ruslan Batiuk | Dreamstime.com
dreamstime_xxl_373539758
By Dragon Claws on Adobe Stock
adobestock_551140731
ID 296570530 © Vetre Antanaviciute-meskauskiene | Dreamstime.com
dreamstime_xxl_296570530